Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd).

Ther Adv Hematol · 2020 · PMC7236395 · PMID 32523660

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

did not reach statistical significancep = 0.061so close (0.05 < p ≤ 0.1)

More specifically, though there was a trend towards better OS in Group 2, the difference did not reach statistical significance ( p = 0.061).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.